FDA Approves Ocrevus Zunovo[TM] as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

- Ocrevus Zunovo[TM] has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office - - This approval is backed [...]